Wockhardt’s novel antibiotic gets CDSCO approval
The antibiotic is an ultra-short course - once-a-day, 3-day treatment for Community-Acquired Bacterial Pneumonia (CABP) in adults, including those caused by multi-drug resistant (MDR) pathogens, the company said